Efficacy and safety of drug with plant extract of saw palmetto in patients with lower urinary tract symptoms because of benign prostatic enlargement
Abstract
Background: Benign prostatic enlargement (BPE) is the most frequent cause of lower urinary tract symptoms (LUTS) in men. The objective of this study was to evaluate the efficacy and safety of Prostasan, the plant extract of saw palmetto in men with LUTS/BPE.
Methods: The study was approved by the Ethical Committee of the Republic of Slovenia. In a prospective, open clinical study, men between 45 and 80 years of age with at least moderate LUTS/BPE, normal serum PSA, in a good physical condition were included after having given their written informed consent . At the beginning of this study, the digito-rectal examination of the prostate was performed together with the evaluation of IPSS and quality of life, total PSA in serum, uroflow and transabdominal US measurement of prostate volume. They were also asked about their erectile dysfunction and libido. All patients received Prostasan 320 mg per day for 12 months. The same parameters as at the beginning of the study were assessed after 6 and 12 months. The subjective assessments of the efficacy and safety of the drug were also recorded byinvestigators and by patients. The side effects of the treatment were recorded at both follow-ups. For statistical analyses, t-test and chi-square tests were used.
Results: 72 men out of 76 (94.7 %) with LUTS/BPE completed the trial. They were 62.7 ± 8.54 years old. IPSS score and quality of life were reduced from 14.46 ± 5.36 to 11.08 ± 3.92 (p = 0.0000) and from 2.72 ± 0,96 to 2.25 ± 1.05 (p = 0.0001) respectively after 12 months of treatment. The uroflow increased from 13.94 ± 5.00 to 15.34 ± 4.07 ml/s (p = 0.0005). Total PSA did not change significantly. After 12 months, prostate volume decreased by 3 % (p = 0.0392). Prostasan had no important influence on erectile function or libido. The majority of patients and doctors rated the efficacy of drug as good (69.7 % and 72.4 % ) and safe (86.8 % and 88.2 %), respectively. Seven patients (9.2 %) reported drug-related side effects.
Conclusions: According to our 12-month clinical trial, we could conclude that Prostasan is a safe and efficient natural drug for the treatment of men with mild to moderate LUTS/BPE.
Downloads
References
Briganti A, Capitanio U, Suardi N, Gallina A, Salonia A, Bianchi M et al. Benign Prostatic Hyperplasia and Its Aetiologies. Eur Urol Suppl 2009; 8: 865–71.
Buck AC. Is there a scientific basis for the therapeutic effects of Serenoa repens in benign prostatic hyperplasia? Mechanisms of action. J Urol 2004; 172: 1792–9.
Habib FK, Wyllie MG. Not all brands are created equal: a comparison of selected components of different brands of Serenoa repens extract. Prostate Cancer Prostatic Dis 2004; 7: 195–200.
Lowe FC. The Role of Serenoa repens in the Clinical Management of Lower Urinary Tract Symptoms Due to BHP. Eur Urol suppl 2009; 8: 894–7.
Djavan B. The Correlation between Inflammation, BPH and Prostate Cancer. Eur Urol suppl 2009; 8: 863–4.
Habib FK, Ross M, Ho Ck, Lyons V, Chapman K. Serenoa repens (Permixon) inhibits the 5alpha--reductase activity of humen prostate cancer cell lines without interfering with PSA expression. Int J Canter 2005; 114: 190–4.
Hill B, Kyprianou N. Effect of Permixon on human prostate cell growth: lack of apoptotic action. Prostate 2004; 61: 73–80.
Vela Navarrete R, Garcia Cordoso JV, Barat A, Manzarbeitia F, Lopez Farre A. BHP and inflammation: pharmacological effect of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol 2003; 44: 549–55.
Wilt TJ, Ishani A, Stark G, MacDonald R, Lau J, Mulrow C. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA 1998; 1604–9.
Byle P, Robertson C, Lowe F, Roehrborn C. Meta--analysis of clinical trials of Permixon in the treatment of symptomatic benign prostatic hyperplasia. Urology 2000; 55: 533–9.
Boyle P, Robertson C, Lowe F, Roehrborn C. Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia. BJU Int 2004; 93: 751–6.
Carraro JC, Raynaud JP, Koch G et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patient. Prostate 1996; 29: 231–40, discussion 241–2.
Debruyne F, Koch G, Boyle P et al. Comparison of a phytotherapeutic agent (Permixon) with an alfa-blocker (tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year rendomized international study. Eur Urol 2002; 41: 497–508, discussion 507.
Bent S, Kane C, Shinohara K et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med 2006; 354: 557–66.
Gerber GS, Kuznetsov D, Johanson BC, Burstein JD. Randomized, double-blind, placebo-controlled trial of saw palmetto in men with LUTS. Urology 2001;58:960–4.
Bauer HW, Casarosa C, Cosci M, Fratta M, Blessmann G. Saw palmetto fruit extract for treatment of BPH. Results of a placebo-controlled double--blind study. Fortschr Med 1999;141:62.
Willetts KE, Clements MS, Champion S, Ehsman S, Eden JA. Serenoa repens extract for BPH: A randomized controlled trial. BJU Int 2003;92:267–70.
Scinescu I, Geavlete P, Multescu R. Long-term efficacy of Serenoa repens treatment in patients with mild and moderate symptomatic BPH. Urol Int 2011;86:284–9.
Suter A, Saller R, Riedi E, Heinrich M. Improving BPH symptoms and sexual dysfunctions with a saw palmetto preparation? Results from a pilot trial. Phytother Res 2012; http://onlinelibrary.wiley.com/advanced/search/results
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
